Amylyx Pharmaceuticals Inc.

Quick facts

Phase 3 pipeline

• AMX0035 · Neurology
  AMX0035 is a fixed-dose combination of sodium phenylbutyrate and taurursodiol that reduces neuroinflammation and protects motor neurons by stabilizing mitochondrial function and reducing ER stress.

Phase 1 pipeline

• AMX0114

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Amylyx Pharmaceuticals Inc. portfolio CI brief
• Amylyx Pharmaceuticals Inc. pipeline updates RSS